Glaxosmithkline Capital Inc
CIK 1224462 · operating company. SEC filings, financial statements, 10-K sections, 8-K items and insider trades for Glaxosmithkline Capital Inc.
Recent SEC filings
| Filed | Form | Accession number |
|---|---|---|
| Sep 10, 2026 | 424B2 | 0001193125-26-387354 |
| Sep 9, 2026 | FWP | 0001193125-26-385861 |
| Sep 8, 2026 | 424B2 | 0001193125-26-384490 |
| Sep 8, 2026 | 6-K | 0001193125-26-384439 |
| Mar 18, 2025 | CERT | 0000876661-25-000200 |
| Mar 13, 2025 | 8-A12B | 0001193125-25-053838 |
| Mar 13, 2025 | 6-K | 0001193125-25-053830 |
| Mar 10, 2025 | 424B2 | 0001193125-25-050728 |
| Mar 7, 2025 | FWP | 0001193125-25-048578 |
| Mar 6, 2025 | 424B2 | 0001193125-25-047959 |
| Mar 25, 2024 | F-3ASR | 0001193125-24-076338 |
| Mar 15, 2023 | EFFECT | 9999999995-23-000582 |
| Mar 10, 2023 | POS AM | 0001193125-23-067243 |
| Sep 15, 2022 | 25-NSE | 0000876661-22-000756 |
| Sep 1, 2022 | 25-NSE | 0000876661-22-000732 |
| Aug 16, 2022 | 6-K | 0001140361-22-029786 |
| Aug 16, 2022 | 6-K | 0001140361-22-029787 |
| Mar 26, 2021 | F-3ASR | 0001193125-21-096095 |
| May 21, 2018 | CERT | 0000876661-18-000564 |
| May 17, 2018 | 25-NSE | 0000876661-18-000539 |
| May 15, 2018 | 6-K | 0001193125-18-164071 |
| May 15, 2018 | 8-A12B | 0001193125-18-164266 |
| May 14, 2018 | 424B2 | 0001193125-18-162878 |
| May 11, 2018 | FWP | 0001193125-18-160226 |
| May 11, 2018 | FWP | 0001193125-18-160222 |